Virtu Financial LLC Makes New Investment in PetMed Express, Inc. (NASDAQ:PETS)

Virtu Financial LLC purchased a new stake in shares of PetMed Express, Inc. (NASDAQ:PETS) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 24,846 shares of the company’s stock, valued at approximately $188,000.

A number of other large investors have also recently made changes to their positions in the stock. Invenomic Capital Management LP purchased a new stake in PetMed Express in the fourth quarter worth approximately $1,631,000. Quest Partners LLC bought a new stake in shares of PetMed Express in the fourth quarter worth $47,000. Trexquant Investment LP grew its holdings in shares of PetMed Express by 110.8% in the fourth quarter. Trexquant Investment LP now owns 113,996 shares of the company’s stock worth $862,000 after acquiring an additional 59,910 shares during the period. Jump Financial LLC lifted its holdings in PetMed Express by 255.2% in the fourth quarter. Jump Financial LLC now owns 60,801 shares of the company’s stock valued at $460,000 after acquiring an additional 43,683 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in PetMed Express by 963.1% in the fourth quarter. BNP Paribas Financial Markets now owns 54,175 shares of the company’s stock worth $410,000 after purchasing an additional 49,079 shares during the last quarter. 73.33% of the stock is currently owned by institutional investors.

PetMed Express Stock Down 2.0 %

Shares of PETS opened at $4.41 on Monday. The business has a 50-day simple moving average of $4.23 and a two-hundred day simple moving average of $5.37. PetMed Express, Inc. has a 52 week low of $3.92 and a 52 week high of $15.08. The stock has a market cap of $90.89 million, a price-to-earnings ratio of -11.31 and a beta of 0.69.

PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, April 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. PetMed Express had a negative return on equity of 7.09% and a negative net margin of 2.85%. The firm had revenue of $65.32 million during the quarter. On average, equities analysts anticipate that PetMed Express, Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PETS shares. Morgan Stanley reduced their price target on shares of PetMed Express from $6.50 to $3.50 and set an “underweight” rating for the company in a research report on Wednesday, June 12th. Lake Street Capital decreased their price target on shares of PetMed Express from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, June 12th.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.